Four-factor prothrombin complex concentrate versus andexanet alfa for direct oral anticoagulant reversal

Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors

Stuart J. Connolly, Mark Crowther, John W. Eikelboom et al. · New England Journal of Medicine · 2019 · 920 citations · Full text

2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants

Gordon F. Tomaselli, Kenneth W. Mahaffey, Adam Cuker et al. · Journal of the American College of Cardiology · 2020 · 327 citations

Thrombosis, Cardiovascular Disease, Oral Anticoagulants +9

Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study

Peter L. Gross, Bruce Ritchie, Susan Nahirniak et al. · Thrombosis and Haemostasis · 2018 · 207 citations

European Stroke Organisation Guideline on Reversal of Oral Anticoagulants in Acute Intracerebral Haemorrhage

Hanne Christensen, Charlotte Cordonnier, Janika Kõrv et al. · European Stroke Journal · 2019 · 145 citations · Full text

Cerebrovascular Disease, Pharmacotherapy, Oral Anticoagulation +21

Evaluation of andexanet alfa and four‐factor prothrombin complex concentrate (4F‐PCC) for reversal of rivaroxaban‐ and apixaban‐associated intracranial hemorrhages

Megan E. Barra, Alvin S. Das, Bryan D. Hayes et al. · Journal of Thrombosis and Haemostasis · 2020 · 106 citations

Intracranial Hemorrhages, Thrombosis, Medicine +13